DCN Dx, a US-based company that deals with the end-to-end development, manufacturing, and commercialisation of point-of-use tests, announced on Wednesday that it has entered into a subcontract agreement with Mapp Biopharmaceutical, Inc., a US-based developer of novel pharmaceuticals for the prevention and treatment of infectious disease.
The subcontract covers the development, optimisation, and deployment of a digitised lateral flow assay to detect circulating Sudan ebolavirus (SUDV) antigen for real-time use in nonclinical studies taking place within biosafety level 4 (BSL4/ABSL4) containment laboratories.
Mitzi Rettinger, DCN Dx's chief revenue officer, said, 'DCN Dx is proud to partner with Mapp Biopharmaceutical to develop medical countermeasures for SUDV. This digitised lateral flow assay will be among the first to offer rapid, cage-side detection of SUDV antigens in nonclinical studies.'
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer